Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Press release cover image

Sep 14, 2026

Press release

Beta Bionics Announces FDA Clearance of Mint™, the Company’s Transformative Patch Pump, and Unveils 3D Intelligence™ as its Next-Generation Insulin Dosing Algorithm

Mint features a new and innovative patch pump architecture Full Mint U.S. commercialization expected to begin in Q1 2027 Manufacturing capacity expected to produce at least 1.5 million disposable Mint units during 20273D Intelligence, the Company’s next-generation insulin dosing algorithm, has been submitted to the FDA through a 510(k) applicationExpectations to commercialize 3D Intelligence in the U.S. by the end of 2026 as iLet 3D™, and at the time of full Mint launch as Mint 3D™, subject to r
Press release cover image

Sep 14, 2026

Press release

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologiesThe unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatmentsInitial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 202
Press release cover image

Sep 14, 2026

Press release

Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas

Pairing year-long continuous glucose monitoring with automated insulin delivery to further simplify diabetes management for patients Brings Eversense 365 to the growing community of iLet Bionic Pancreas users Plan for commercial launch of the integrated system in Q4 2026 GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), maker of the Eversense 365 Continuous Glucose Monitoring (CGM) System, the world’s first and only long-term, one-year implantable se
Press release cover image

Sep 14, 2026

Press release

Asimov Announces Cell Line Development Partnership with Sidewinder Therapeutics to Advance 4-Chain Bispecific Antibody for Solid Tumors

BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific ADCs (antibody-drug conjugates) for the treatment of cancer. As part of a broader collaboration across multiple products, Asimov successfully delivered a cell line for Sidewinder’s bi
Press release cover image

Sep 14, 2026

Press release

Kyndryl completes acquisition of Healthcare IT Leaders, LLC

Acquisition to accelerate AI-led modernization for healthcare providers and payorsNEW YORK, Sept. 14, 2026 /PRNewswire/ -- Kyndryl (NYSE: KD), a leading provider of mission-critical enterprise technology services, today announced it has completed its acquisition of Healthcare IT Leaders, LLC, an enterprise IT services provider serving hospitals and health systems across the United States, for up to $350 million, including a contingent performance-based earnout. The transaction follows Kyndryl's
A biopsy sample on a microscope slide in a dim laboratory setting.

Sep 14, 2026

AstraZeneca’s AI Pathology Study Signals Next Wave in Cancer Diagnostics

AstraZeneca has provided an update on its clinical study examining the integration of AI and computational pathology in diagnosing suspected non-small cell lung cancer and breast cancer.The study, which is observational in nature, evaluates how pathologists utilize digital tools in real-world settings. By analyzing existing patient samples, the research aims to determine how AI can enhance diagnostic accuracy and efficiency, potentially influencing the demand for targeted cancer therapies and th
A minimalist illustration of a test tube with a blood sample in a laboratory setting.

Sep 14, 2026

EXCLUSIVE: Switzerland’s Aeon acquires Aware Health as total Seed funding surpasses €12 million

Switzerland's Aeon has successfully extended its Seed funding and acquired Aware Health, a German blood diagnostics platform, marking a significant milestone in its mission to redefine preventive healthcare.Aeon, based in Zurich, has now raised over €12 million in total Seed funding, building on its previous €8.2 million round from June 2025. This extension was co-led by Araya Ventures, with contributions from several existing investors. The company aims to transform preventive care by integrati
A syringe on a medical chart in a clinical setting

Sep 14, 2026

Stockholm’s Tandem Health raises €86.5 million to build an AI-native operating system for European healthcare

Stockholm-based Tandem Health has successfully secured €86.49 million ($100 million) in Series B funding to develop an AI-native operating system tailored for European healthcare. This funding round, led by the Scaleup Europe Fund, marks a significant milestone in the company's journey, which has now totaled €138.38 million ($160 million) since its inception.Tandem Health, founded in 2023, aims to address the pressing challenges faced by European healthcare systems, including rising costs and cl
A minimalist illustration of a cell and an analyzer device in a lab setting.

Sep 14, 2026

Vi-CELL BLU 2.0 software boosts GMP readiness

Beckman Coulter Life Sciences has introduced the Vi-CELL BLU 2.0 Viability Analyzer Software, a significant upgrade designed to enhance cell viability workflows while ensuring compliance and data integrity.This new software version aims to facilitate the transition from research to biomanufacturing by providing laboratories with advanced cell analysis tools. It builds upon the existing Vi-CELL BLU instrument, featuring improved algorithms for cell counting and customizable analysis settings that
Press release cover image

Sep 14, 2026

Press release

Aignostics lanza PathoSearch, un motor de búsqueda visual para casos de patología

Ya disponible en acceso anticipado: la búsqueda basada en imágenes recupera casos de referencia reales y diagnosticados de centros de renombre mundial, que abarcan más de 300 entidades diagnósticas.BERLIN y NUEVA YORK, 14 de septiembre de 2026 /PRNewswire/ -- Aignostics anunció el pasado día 12 el lanzamiento en acceso anticipado de PathoSearch, un motor de búsqueda visual para casos de patología. A partir de una sola captura de pantalla de una región de interés en una diapositiva de H&E, Pa
IV drip in an emergency department

Sep 14, 2026

Medtech: NSW hospitals to trial AI model to detect sepsis faster

NSW Health is set to enhance the early detection of sepsis through an AI prediction model, supported by a significant investment from the government.The SAFE-WAIT initiative aims to assist healthcare professionals in identifying patients at varying risk levels for sepsis while they await treatment in emergency departments. With nearly $500,000 allocated from the government’s broader $4.9 million fund for impactful research, this project builds on a successful pilot at Westmead Hospital in 2024,
Press release cover image

Sep 14, 2026

Press release

Omniscient Secures Third FDA Clearance, Extending Its Connectomic Platform into the Fast-Growing Deep Brain Stimulation Market

The clearance of Quicktome’s Deep Brain (DB) workflow marks Omniscient's third FDA milestone and its entry into DBS, advancing the company's strategy to provide actionable brain insights across neurosurgery and neurologyOmniscient's Quicktome Deep Brain (DB) workflowSYDNEY, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Omniscient today announced 510(k) clearance from the U.S. Food and Drug Administration for a new workflow within the Quicktome® platform: Quicktome Deep Brain (DB) is a new application that